Sigyn Therapeutics, Inc. has reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a net loss of $2.7 million for the nine-month period, a slight improvement from a loss of $2.8 million during the same period in 2024. The company continues to operate without generating any revenue, maintaining a focus on developing its innovative blood purification technology, CardioDialysis™, aimed at treating cardiovascular disease. Operating expenses for the nine months decreased by 31.3% to approximately $1.4 million, primarily due to reduced research and development costs and other operational efficiencies.
The company’s total assets as of September 30, 2025, were reported at $135,571, a significant decline from $213,719 at the end of 2024. This decrease is attributed to a reduction in cash reserves, which stood at $85,571 compared to $12,144 at the end of the previous fiscal year. Total liabilities increased to $6.1 million, up from $4.7 million, largely due to rising accounts payable and accrued payroll expenses. The accumulated deficit has also grown to $17.4 million, reflecting the ongoing challenges of funding operations without revenue.
In terms of strategic developments, Sigyn Therapeutics has filed a trademark application for CardioDialysis™ with the United States Patent and Trademark Office, indicating a shift in focus towards cardiovascular disease treatment. This strategic pivot is expected to facilitate easier enrollment in clinical studies, as the company aims to leverage existing dialysis infrastructure to conduct its clinical trials. The company is also exploring additional funding avenues, including public offerings and asset sales, to support its operations and development plans.
Operationally, the company has seen a reduction in its employee headcount and has made organizational changes, including the resignation of several board members due to the discontinuation of liability insurance coverage. The company’s management has acknowledged the need for additional capital to sustain operations, with plans to enhance internal controls and financial reporting processes in response to identified weaknesses. Looking ahead, Sigyn Therapeutics remains focused on advancing its clinical programs and securing the necessary funding to continue its development efforts, although uncertainties regarding future financing persist.
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics develops medical devices focused on blood purification to treat infectious diseases, sepsis, and inflammatory disorders. Its flagship Sigyn Therapy extracts pathogens, toxins, and cytokines from blood, addressing unmet needs like viral infections, antibiotic resistance, and sepsis. The company also innovates devices to enhance cancer drug delivery and reduce toxicity, targeting global health challenges with broad-spectrum, extracorporeal solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.